LYMPHOMAS

Julie Vose, MD, discusses the exciting developments across lymphomas.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

Following voluntary withdrawal in 2014, denileukin diftitox is now available again for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.

ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.

During a Case-Based Roundtable® event, Joanna M. Rhodes, MD, MSCE, discussed issues related to toxicity and dose modification in treating patients with Hodgkin lymphoma.

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.

The FDA has approved the CAR T-cell therapy liso-cel for the treatment of patients with mantle cell lymphoma.

A study found that a novel ointment improved symptoms in patients with cutaneous T-cell lymphoma. The treatment was well-tolerated with minimal adverse effects.

With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in relapsed/refractory B-cell non-Hodgkin lymphomas will begin.

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.

Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.

Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.

The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.

An investigational new drug application for SynKIR-310's phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.

The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.

The FDA issued a pair of complete response letters for the biologics license application for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.

If approved, denileukin diftitox could offer a valuable addition to the treatment landscape of relapsed/refractory cutaneous T-cell lymphoma.

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.